deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT01844947

Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract (VINSOR)

An Exploratory Phase I Study With Sorafenib in Addition to Vinflunine in Progressive Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract

Sponsor: Bayer

Conditions Bladder Cancer Renal Pelvis Cancer Ureter Cancer Urethra Cancer Urothelial Carcinoma
Interventions Sorafenib Vinflunine
Updated 8 times since 2017 Last updated: Apr 25, 2019 Started: May 31, 2012 Primary completion: Oct 18, 2017 Completion: Jun 5, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Bladder Cancer and Renal Pelvis Cancer, this trial is completed. The trial is conducted by Bayer and has accumulated 8 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Jan 2018 · 12 months · monthly snapshotRecruiting~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshotActive Not Recruiting~Sep 2018 – ~May 2019 · 8 months · monthly snapshotCompleted~May 2019 – ~Jan 2021 · 20 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. May 2019 — Jan 2021 [monthly]

    Completed PHASE1

  5. Sep 2018 — May 2019 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 3 earlier versions

  1. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE1

  2. Jan 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  3. Jan 2017 — Jan 2018 [monthly]

    Recruiting PHASE1

    First recorded

May 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
  • Dr Anders Ullén
  • Nordic Urothelial Cancer Oncology Group
  • Pierre Fabre Laboratories
Data source: Karolinska University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations